Vicore Pharma to Attend Two Investor Conferences in London in November 2017
Vicore Pharma will present at the Biotech and Money Inv€$tival Showcase in partnership with Jefferies and host one-to-one meetings at the Jefferies 2017 London Healthcare Conference
Vicore Pharma Holding (publ) (ticker:VICO), announced today that its CEO, Per Jansson, is scheduled to present at the Biotech and Money Inv€$tival showcase on Tuesday, November 14, 2017, at the Waldorf Hilton Hotel in London, UK at 1:45 p.m. GMT and will attend the Jefferies 2017 London Healthcare Conference, November 15-16, 2017, also at the Waldorf Hilton Hotel in London.
Vicore Pharma’s CEO, Per Jansson, CFO, Hans Jeppsson and CSO, Ulrike Muscha Steckelings will be hosting one-to-one meetings with investors at both conferences.
Investors attending both or either of the two conferences who wish to meet with senior management for a one-to-one meeting should either notify their Jefferies representative or send direct inquiry to the company’s Investor Relations contact:
The Blueshirt Group
T: +46 79 348 6277
About the conferences:
Biotech and Money Inv€$tival showcase, November 14, London UK
Biotech and Money connects corporates to capital, and the Inv€$tival Showcase in partnership with Jefferies presents the latest investable private and public life science opportunities to our growing investor network and that of Jefferies LLC.
Jefferies Healthcare conference, November 15-16, London UK
Now in its eighth year, the Jefferies Conference is the largest healthcare-dedicated conference in Europe. This year, we hosted 350 participating companies, 1,400 attendees and 3,400 investor and business-to-business meetings. The event featured leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors from the United States, Europe, Africa, Middle East, Latin America, Russia, India, Israel, China and Japan.
About Vicore Pharma Holding
Vicore Pharma develops drugs that act through the AT2 receptor. The company’s drug candidate C21 aims to improve the treatment of idiopathic pulmonary fibrosis, a rare disease for which C21 has been granted orphan drug designation both in the EU and the US. In addition, C21 is explored pre-clinically in a number of rare diseases where the AT2 receptor plays an important role. Vicore Pharma is based in Astra Zeneca's Bioventurehub in Mölndal. The company's share (VICO) is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser. For more information, see www.vicorepharma.com